Medtronic plc
MDT · NYSE · Healthcare
+$4.20 today
- Mkt cap $100.08B
- P/E 21.8
- Day $76.27 – $78.35
Confidence
High conviction
The read
Medtronic's Q4 earnings reported without EPS data; shares rise 5.7% amid cautious sentiment
Medtronic reported Q4 earnings without releasing actual EPS, shares gained 5.7% despite uncertainty from a neuromodulation software recall. Valuation remains attractive but growth metrics lag sector averages.
Confidence note: Data lacks reported EPS but includes strong valuation and institutional ownership; recall risk adds uncertainty.
What happened
Earnings print
Guidance
Price reaction
Street narrative
So what
What changed
What the market is pricing
Fundamental takeaway
Next 30–90 days
Recall impact is limited; neuromodulation sales recover, supporting earnings growth and valuation re-rating.
- boltPositive neuromodulation sales data within next quarter
- boltNo further recall-related disruptions reported
Recall causes moderate sales disruption; growth slows but valuation support limits downside.
- boltStable but subdued neuromodulation sales
- boltNo significant negative guidance revisions
Recall severely disrupts neuromodulation sales, leading to earnings misses and valuation multiple contraction.
- boltSignificant neuromodulation sales decline reported
- boltNegative guidance updates or analyst downgrades
What to do
If you hold it
If you're watching
Keep on your radar
- Neuromodulation segment sales data next quarter
- Company guidance updates by next earnings call
- Analyst rating changes within 90 days
- Recall resolution progress reports